Wood N B, Kotelnikov V, Caldarelli D D, Hutchinson J, Panje W R, Hegde P, Leurgans S, LaFollette S, Taylor S G, Preisler H D, Coon J S
Department of Pathology, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois 60612, USA.
Laryngoscope. 1997 Jun;107(6):827-33. doi: 10.1097/00005537-199706000-00019.
Rapid proliferation of squamous cell carcinomas of the head and neck (SCCHN) during therapy may contribute to treatment failure. We have investigated the presence of p53 abnormalities in patients with SCCHN as a correlate of proliferation rate and other pathologic and clinical variables. p53 Mutation, as determined by polymerase chain reaction and single-strand conformation polymorphism analysis of microdissected frozen sections of tumor biopsies, was significantly associated with a high labeling index, as determined by in vivo infusion of IUdR and BrdU (P = 0.017). p53 Protein expression was detected by immunohistochemistry with two different antibodies, followed by quantitative image analysis. Many cases exhibited strong p53 protein expression in the absence of mutations within the conserved region of the gene, and expression was not related to proliferation. The presence of p53 mutations was related to tumor differentiation in this group of patients.
